Sanger Sequencing Service for Clinical Decisions
Sanger sequencing is the superior method for sequencing, and it is a process of incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication. Sanger sequencing is known to provide high accuracy, long-read capabilities, and adaptability to support a diverse range of applications in many research areas. Sanger sequencing is mainly recognized for DNA sequencing and supports applications in RNA sequencing and epigenetic analysis.
In many clinical studies, in different groups of subjects, substantive insights have been made by comparing the primary DNA sequences of genes. For example, As per Thermo Fisher Scientific, a recent study showed that up to 2% of the variants detected by NGS were not reproducible by Sanger sequencing. Therefore, in many clinical studies before a firm conclusion from variants identified by NGS, it should be confirmed by an orthogonal method. Reference materials sequenced by Sanger approaches provide ground truth against which the NGS assay can be benchmarked.
Download PDF Brochure Study Here
Many of the evolving biotechnology and genetics start-ups are using DNA sequencing technologies for various applications. These new emerging companies are offering sequencing services that analyze human and animal genomes. For instance, located in Baltimore, United States, Personal Genome Diagnostics Inc. was founded in 2010 and is involved in genome analysis of human tumors. The company develops a patient-specific analysis of cancer by using sequencing tools and technologies.
Sanger sequencing has long been viewed as the gold standard for sequencing technology. It enables a high degree of accuracy, provides long-read capabilities, and has the flexibility to support a diverse range of applications in both the research and clinical arenas. AKESOgen offers sequencing services that are optimized for the rapid turnaround of high quality sequence data for individual samples or high-throughput plate sequencing. The ABI 3730XL Sanger sequencing platform uses capillary electrophoresis and typically generates sequences with read lengths up to 1200 bp.
Sanger sequencing is still used widely for targeted sequencing of clinically relevant germline mutations, pathogen identification, and confirming the genomic variants identified by non-sequencing (DNA hybridization and PCR based) methods. However, Sanger sequencing is cost prohibitive and inefficient for simultaneous sequencing of multiple genes, the entire genome or metagenome, and detection of low frequency mutations.
A major breakthrough was the Sanger sequencing method developed by Frederick Sanger in 1977, which has since been automated in the form of the capillary sequencing method commercialized by Applied Biosystems Inc. (ABI). Sanger sequencing is based on the selective incorporation of chain-terminating and fluorescently labeled dideoxynucleotides (ddNTPs) during pre-sequencing PCR, also known as cycle sequencing PCR.
References:
https://www.theinsightpartners.com/pr/sanger-sequencing-service-market
https://www.labmanager.com/insights/sanger-sequencing-still-the-gold-standard-1758